A string of bad events in the South Korean bio industry are fueling concerns that a “K-biotech stock bubble” might burst.According to industry sources on July 23, SillaJen Inc., one of South Korea's top biotherapeutics companies, has encountered criticism from its shareholders as executive offic
Dong-A ST said on September 12 that Tobira Therapeutics Inc. (CEO Laurent Fischer) has recently initiated conducting a phase 1 study of the combination therapy of Evogliptin and Cenicriviroc (CVC) so as to develop a composite drug of non-alcoholic steatohepatitis (NASH).In compliance with an agreeme
Dong-A ST Co. announced on Apr. 11 that it has entered into a license agreement with Tobira Therapeutics to develop Evogliptin as a treatment of non-alcoholic steatohepatitis (NASH).Under the terms of the agreement, Dong-A ST will receive up to US$61.5 million (70.54 billion won) from Tobira, includ